GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ViaDerma Inc (OTCPK:VDRM) » Definitions » Net Cash per Share

VDRM (ViaDerma) Net Cash per Share : $-69.53 (As of Jun. 2012)


View and export this data going back to 2008. Start your Free Trial

What is ViaDerma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). ViaDerma's Net Cash per Share for the quarter that ended in Jun. 2012 was $-69.53.

The historical rank and industry rank for ViaDerma's Net Cash per Share or its related term are showing as below:

VDRM's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.69
* Ranked among companies with meaningful Price-to-Net-Cash only.

ViaDerma Net Cash per Share Historical Data

The historical data trend for ViaDerma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViaDerma Net Cash per Share Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
Net Cash per Share
- -272.20 -42.38 -42.92 -61.96

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.03 -72.67 -61.96 -68.77 -69.53

Competitive Comparison of ViaDerma's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViaDerma's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where ViaDerma's Price-to-Net-Cash falls into.



ViaDerma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

ViaDerma's Net Cash per Share for the fiscal year that ended in Dec. 2011 is calculated as

Net Cash per Share (A: Dec. 2011 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.578-9.086-0)/0.13732
=-61.96

ViaDerma's Net Cash per Share for the quarter that ended in Jun. 2012 is calculated as

Net Cash per Share (Q: Jun. 2012 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1.187-10.735-0)/0.13732
=-69.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViaDerma  (OTCPK:VDRM) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


ViaDerma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of ViaDerma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ViaDerma Business Description

Traded in Other Exchanges
N/A
Address
4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.

ViaDerma Headlines

From GuruFocus

ViaDerma Inc., Provides Review of 2020 and Looks Forward to 2021

By Marketwired Marketwired 01-13-2021

ViaDerma, Inc. Provides a Corporate Update

By Marketwired Marketwired 01-16-2020

ViaDerma, Inc. Provides a Corporate Update

By GlobeNewswire GlobeNewswire 01-16-2020

ViaDerma Provides an Update on Current & Future Business Activities

By sperokesalga sperokesalga 03-02-2023

ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development

By Stock market mentor Stock market mentor 01-12-2023

ViaDerma, Inc. Nearing Initial Order from Large Hospital Network

By Marketwired Marketwired 05-13-2021

ViaDerma, Inc. Provides a Corporate Update

By Marketwired Marketwired 06-23-2020